drugset / Trial / NCT03340324

Open Label Immunotherapy of Endometriosis

NCT03340324 ↗

Phase 2 Unknown 30 enrolled Immunitor LLC Ekomed LLC · collab
NaSingle-groupOpen-labelTreatment

Summary

Endometriosis is a chronic gynecological disease characterized by sustained painful symptoms that are responsible for a decline in the quality of life of sufferers. Endometriosis is fairly common, affecting an estimated 10%-15% of women and girls, usually during their reproductive years. Based on these rough estimates, the latest epidemiological studies suggest that over 200 million women are might be affected who may commonly have infertility problems. Additionally, endometriosis is a major factor increasing by 33-66% risk of ovarian cancer. V-Endo is a tableted preparation derived from hydrolyzed, heat-inactivated, pooled blood of women with endometriosis. When taken orally it is postulated to cause the immune tolerance and anti-inflammatory effect as a result.

Timeline

Start
2017-10-01
Primary completion
2019-12-01
Completion
2019-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject V-Endo Unknown — Oral

Indications